CliffBio
biologic

Libtayo

cemiplimab-rwlc

Loss of exclusivitySeptember 2030projected — 12-year biologic exclusivity estimate
CompanyRegeneron Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameLibtayo
Active ingredientcemiplimab-rwlc
Strength350MG/7ML (50MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalSeptember 2018
Marketing statusRx

More from Regeneron Pharmaceuticals

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Libtayo patent cliff — loss of exclusivity September 2030 | CliffBio